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Abstract: Erdheim–Chester disease is a rare form of non-Langerhans
cell histiocytosis characterized by the migration and infiltration of lipid-
laden CD68þ, CD1a and S100 histiocytes to various target organs,
which leads to the disruption of physiological tissue architecture and
reactive fibrosis, and thus impairs organ function.
We describe the first case of a patient with Erdheim–Chester disease
with multiorgan involvement developed after 6 years from polycythe-
mia vera diagnosis. During the follow-up, an abdominal ultrasound scan
revealed the presence of dense, bilateral perinephric infiltration. A
computed tomographic guided core biopsy was performed in order to
identify the histological nature of this lesion, and a morphological
analysis demonstrated the accumulation of foamy histiocytes sur-
rounded by fibrosis. The BRAFV600E mutation was detected, and a
diagnosis of Erdheim–Chester disease was made.
The extreme rarity of Erdheim–Chester disease strongly suggests
the existence of potentially common element(s) that may have con-
tributed to the pathogenesis of both disorders. Obviously, further
studies are needed to clarify the mutual roles and effects of JAK2
andBRAFmutations in this patient, as well as their possible therapeutic
implications.
(Medicine 95(20):e3697)dio Doglioni, MD, elli, MD,
rtelezzi, MD
myeloproliferative neoplasm, PV = polycythemia vera, TNF-a =
tumor necrosis factor alpha, WHO = World Health Organization.
INTRODUCTION
E rdheim–Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis characterized by the migration
and infiltration of lipid-laden CD68þ, CD1a, and S100
histiocytes to various target organs, which leads to the disrup-
tion of physiological tissue architecture and reactive fibrosis,
and thus impairs organ function.1,2 It seems to have a slight
male predominance, the majority of the patients are diagnosed
between the ages of 40 and 70 years,3 and its severity ranges
from mild to life-threatening depending on the site(s) of
involvement.4
It has been found that ECD histiocytes express a pro-
inflammatory network of cytokines and chemokines that is
responsible for local activation and recruitment of other patho-
logical histiocytes.5 They also bear activating mutations in the
MAPK-activating pathway, of which NRAS and PIK3CA
mutations have so far been described in only a few cases,
but the BRAFV600E mutation seems to be present in most
patients.6,7
On the basis of these findings, ECD is now considered to
be a clonal disorder associated with the development of a local
and systemic pro-inflammatory milieu that plays a crucial role
in its pathogenesis and clinical manifestations.8
Associations between ECD and other hematological
malignancies have been rarely reported,9 and there is no pre-
viously published case involving the coexistence of ECD and
BCR-ABL1-negative myeloproliferative neoplasms (MPNs).
Polycythemia vera (PV) is an MPN that is mainly characterized
by increased red cell mass, frequently associated with leuko-
cytosis and thrombocytosis.10 Sixty percent of PV patients are
older than 60 years, and there is no difference in gender
distribution.11 Almost all of the patients present the JAK2V617F
mutation and, albeit to a lesser extent, mutations in the gene’s
exon 12. Furthermore, PV is typically associated with an
increased risk of thrombosis and a long-term tendency to
transform itself into post-PV myelofibrosis (15–20%)12 and/
or acute myeloid leukemia (5–8%).11
We here describe for the first time the case of a patient with
a previous diagnosis of PV who developed ECD with multi-
organ involvement after 6 years of hematological follow-up.
CASE REPORT
an was admitted into our Hospital in
splenomegaly, a high red cell count,
erythropoietin levels. Cytogenetic
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analysis showed a normal male karyotype. Molecular studies
were negative for the BCR-ABL1 rearrangement, but revealed
the JAK2V617F mutation with an allele burden of 44.9%. A
diagnosis of PV was made on the basis of a morphological bone
marrow analysis according to the WHO 2008 criteria. The
patient was started on aspirin, hydroxyurea, and phlebotomies,
all of which were well tolerated.
Six years later, an abdominal ultrasound scan revealed the
presence of dense bilateral perinephric infiltration, which was
confirmed by a whole-body computed tomography (CT) scan, and
a fluotine-18 fluordeoxyglucose positron emission tomography
(F-FDG-PET) scan demonstrated increased glucose uptake in the
medullary channels of both humeri and femurs. Morphological
bone marrow analysis confirmed the previous diagnosis of PV and
showed no evident change in the grading of bone marrow fibrosis
(MF-0 according to the EUMNET consensus),13 whereas cyto-
genetic analysis revealed the following complex male karyotype:
47,XY,þ9[2/20],47,XY,add(6)(p25),þ9[2/20],46,XY[16/20].
The histological nature of the perinephric infiltration was
identified by means of a CT-guided core biopsy of the lesion.
Morphological analysis demonstrated the accumulation of
foamy histiocytes that were positive for CD68 and negative
for the dendritic cell markers CD1a and S100, surrounded by
fibrosis and a scanty lympho-monocytic infiltrate (Figure 1).
The detection of the BRAFV600E mutation led to a diagnosis
of ECD. Cardiac magnetic resonance imaging (MRI) revealed
pseudo-tumoral infiltration of the atrioventricular wall,14 and
a bone scan showed symmetrically irregular radiotracer
uptake in the long bones of the limbs consistent with ECD
(Figure 2)2; the findings of cerebral and pulmonary imaging
were negative. In accordance with the most recent guidelines
for the treatment of ECD,1 the patient started therapy with
Iurlo et alpegylated interferon (IFN)-alpha and, after 3 months of
treatment, a new abdominal ultrasound scan revealed the
complete resolution of the dense bilateral perinephric
FIGURE 1. A, Morphological bone marrow analysis confirming the p
fibrosis or blast percentage, and no significant lymphoid infiltrate. B, C
accumulation of foamy histiocytes positive for CD68 and negative for
and a scanty lympho-monocytic infiltrate.
2 | www.md-journal.cominfiltration, and the normalization of the blood cell counts
was achieved.
DISCUSSION
ECD is an extremely rare hematological disorder, as only
about 600 cases have been reported in the literature2; PV is also
an infrequent disease, with an estimated annual incidence of 2/
100,000 people.10 To the best of our knowledge, there is only 1
published report describing ECD in association with another
hematological neoplasms: the case of a 14-year-old girl with
pre-B cell acute lymphoblastic leukemia in remission who was
subsequently diagnosed as having ECD.9 There are no pre-
viously published descriptions of the coexistence of ECD and
PV or other BCR-ABL1-negative MPNs.
A critical step in our understanding of the exact pathogenic
mechanism underlying PV was the discovery of the
JAK2V617F-acquired activating somatic mutation in 2005.15
Unlike the other BCR-ABL1-negative MPNs, about 95% to 97%
of all cases of PV are characterized by the presence of this
mutation, which is not seen in patients with lymphoid neo-
plasms or reactive myeloproliferation, or in healthy volunteers.
JAK2V617F is due to a somatic G to T mutation involving JAK2
exon 14, and affects the noncatalytic ‘‘pseudo-kinase’’ domain
by derailing its kinase regulatory activity. The constitutive
activity of JAK2 mainly leads to an excessive transcription
of cell survival promoting, anti-apoptotic molecules, and an
increased production of pro-inflammatory cytokines, such as
interleukin (IL)-6, tumor necrosis factor alpha (TNF-a), IL-8,
IL-2R, IL-12, and IL-15 by pathological megakaryocytes and
monocytes.16 As JAK2V617F does not seem to be the disease-
initiating event but probably defines an MPN subclone, the
possibility of the independent emergence of multiple abnormal
Medicine  Volume 95, Number 20, May 2016clones has recently been suggested, which challenges the pre-
vailing view that an abnormal ancestral clone gives rise to
mutually exclusive subclones.
revious diagnosis of PV, with no evident change in bone marrow
T-guided biopsy of the perinephric infiltrating lesion showing the
the dendritic cell markers CD1a and S100, surrounded by fibrosis
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FIGURE 2. A, Contrast-enhanced abdominal CT scan showing solid vascularized tissue located in the retroperitoneal space surrounding
loc
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acquire additional somatic mutations, including those of the
BRAF gene,17 which is involved in the cell signal transduction
that directs cell growth and many other physiological processes,
and whose activation is the final downstream component of
various signal transduction pathways, including the JAK-STAT
pathway. As the cytokine milieu described in PV shares sig-
nificant similarities to that which promotes histiocyte recruit-
ment, activation, and enhanced survival in ECD lesions,5,8 it is
tempting to speculate that the pro-inflammatory effects of the
JAK2V617F mutation may have contributed to the pathogenesis
of ECD in our patient. It is important to remember that
mutations leading to JAK-STAT pathway activation have been
previously described in solid tumors such as head and neck
squamous cell carcinomas, hepatitis B associated hepatocellular
carcinomas, gastric adenocarcinomas, prostate cancer, non-
small cell lung cancer, and glioblastomas.18
Low-dose aspirin and phlebotomies can be effectively and
safely used to treat PV in low-risk patients, whereas hydro-
xyurea is usually added when treating those at high risk.19
Another treatment option is IFN-alpha, which can reduce the
mutant clone,20,21 control constitutional and microvascular
symptoms, and prevent thrombo-hemorrhagic complications
in most cases. Furthermore, targeted therapies (mainly JAK1/
2 inhibitors) are now available and have led to promising results
especially in patients who are resistant or intolerant to hydro-
xyurea.22
ECD therapy is recommended for all patients at the time of
diagnosis, except those with minimally symptomatic disease.
the kidneys, ureters and aorta. B, Cardiac MRI showing a mass
symmetrically irregular radiotracer uptake in the long bones of thThe possible therapeutic options include IFN-alpha-2a, pegy-
lated IFN-alpha, corticosteroids, and imatinib, but no standard
treatment regimen has yet been established.1
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Interestingly, it has been reported that treatment with the
BRAF inhibitor vemurafenib can lead to unprecedented clinical
and radiographic improvements in ECD patients bearing the
BRAFV600E mutation, but it has so far only been used in a very
small number of patients enrolled in clinical trials.23,24 Further-
more, as BRAF is the final downstream component of the JAK-
STAT pathway, it can be speculated that JAK1/2 inhibitors such
as ruxolitinib could also be used to treat ECD.
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